20.06 14:13 | dpa-AFX: *ABBOTT COLLABORATES WITH NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS TO ENHANCE NUTRITIONAL ACCESS &HEALTH OUTCOME |
14.06 19:48 | dpa-AFX: *ABBOTT DECLARES QUARTERLY DIVIDEND OF $0.55/SHARE, PAYABLE AUG. 15/ RECORD JULY 15 |
14.06 19:35 | dpa-AFX: *ABBOTT LABORATORIES (ABT) DECLARES QUARTERLY DIVIDEND OF $ 0.55, RECORD DATE 7/15/2024 |
10.06 15:30 | dpa-AFX: Abbott's Lingo, Libre Rio OTC Continuous Glucose Monitoring Systems Gets FDA Clearance |
10.06 14:01 | dpa-AFX: *ABBOTT GETS FDA CLEARANCE FOR TWO NEW OVER-THE-COUNTER CONTINUOUS GLUCOSE MONITORING SYSTEMS |
30.05 12:34 | dpa-AFX: *GOLDMAN STARTET ABBOTT LABORATORIES MIT 'BUY' - ZIEL 121 USD |
30.05 12:34 | dpa-AFX: *GOLDMAN STARTS ABBOTT LABORATORIES WITH 'BUY' - PRICE TARGET 121 USD |
29.04 16:10 | dpa-AFX: Abbott's Dissolving Stent For People With Chronic Limb-Threatening Ischemia Gets FDA Nod |
29.04 15:04 | dpa-AFX: *FDA OKS ABBOTT'S ESPRIT BTK EVEROLIMUS ELUTING RESORBABLE SCAFFOLD SYSTEM FOR CHRONIC LIMB-THREATENING ISCHEMIA |
17.04 22:15 | MÄRKTE USA/Leichter - Halbleiterwerte unter Druck |
17.04 18:16 | MÄRKTE USA/Leichter - Halbleiterwerte unter Druck |
17.04 15:42 | MÄRKTE USA/Etwas fester - Sinkende Marktzinsen stützen Aktien |
17.04 15:31 | dpa-AFX: *ABBOTT LABORATORIES -1% WENIG BEWEGT NACH QUARTALSZAHLEN |
17.04 14:42 | MÄRKTE USA/Gut behauptet - ASML könnte Technologiewerte bremsen |
17.04 13:52 | dpa-AFX: ROUNDUP: Abbott Laboratories Q1 Earnings Fall, But Ups Annual Earnings Outlook |
17.04 13:37 | dpa-AFX: *ABBOTT NARROWS 2024 ORGANIC SALES GROWTH GUIDANCE RANGE, EXCL. COVID-19 TESTING-RELATED SALES, TO 8.5% TO 10.0% |
17.04 13:37 | dpa-AFX: *ABBOTT LABORATORIES VORBÖRSLICH -0,2% NACH QUARTALSZAHLEN |
17.04 13:36 | dpa-AFX: *ABBOTT PROJECTS FULL-YEAR EPS OF $3.25 TO $3.40 AND ADJ. EPS OF $4.55 TO $4.70 |
17.04 13:35 | dpa-AFX: *ABBOTT PROJECTS Q2 EPS OF $0.69 TO $0.73, ADJ. EPS OF $1.08 TO $1.12 |
17.04 13:34 | dpa-AFX: *ABBOTT Q1 NET SALES $9.96 BLN VS $9.75 BLN PRIOR YEAR |
|